Characteristic | HR+/HER2-, N (%) | HR−/HER2+, N (%) | HR+/HER2+, N (%) | Triple-negative, N (%) | p value |
---|---|---|---|---|---|
All patients | 386 (47.7) | 116 (14.3) | 130 (16.1) | 177 (21.9) | Â |
Age | Â | Â | Â | Â | 0.015 |
  < 50 | 172 (44.6) | 44 (37.9) | 62 (47.7) | 99 (55.9) |  |
  ≥ 50 | 214 (55.4) | 72 (62.1) | 68 (52.3) | 78 (44.1) |  |
ECOG | Â | Â | Â | Â | 0.194 |
 0 | 91 (23.6) | 24 (20.7) | 23 (17.7) | 46 (26.0) |  |
 1 | 278 (72.0) | 88 (75.9) | 102 (78.5) | 117 (66.1) |  |
 2 | 17 (4.4) | 4 (3.4) | 5 (3.8) | 14 (7.9) |  |
Pathological type | Â | Â | Â | Â | 0.552 |
 IDC | 355 (92.0) | 111 (95.7) | 125 (96.2) | 168 (94.9) |  |
 ILC | 9 (2.3) | 1 (0.9) | 2 (1.5) | 3 (1.7) |  |
 Others | 22 (5.7) | 4 (3.4) | 3 (2.3) | 6 (3.4) |  |
T-stage | Â | Â | Â | Â | 0.065 |
 T1 | 104 (26.9) | 24 (20.7) | 32 (24.6) | 47 (26.6) |  |
 T2 | 169 (43.8) | 50 (43.1) | 52 (40.0) | 83 (46.9) |  |
 T3 | 20 (5.2) | 6 (5.2) | 5 (3.8) | 17 (9.6) |  |
 T4 | 18 (4.7) | 12 (10.3) | 9 (6.9) | 6 (3.4) |  |
 Unknown | 75 (19.4) | 24 (20.7) | 32 (24.6) | 24 (13.6) |  |
N-stage | Â | Â | Â | Â | 0.005 |
 N0 | 113 (29.3) | 25 (21.6) | 30 (23.1) | 65 (36.7) |  |
 N1 | 96 (24.9) | 23 (19.8) | 43 (33.1) | 45 (25.4) |  |
 N2 | 66 (17.1) | 22 (19.0) | 23 (17.7) | 31 (17.5) |  |
 N3 | 67 (17.4) | 35 (30.2) | 20 (15.4) | 19 (10.7) |  |
 Unknown | 44 (11.4) | 11 (9.5) | 14 (10.8) | 17 (9.6) |  |
M-stage | Â | Â | Â | Â | 0.002 |
 M0 | 339 (87.8) | 88 (75.9) | 103 (79.2) | 157 (88.7) |  |
 M1 | 47 (12.2) | 28 (24.1) | 27 (20.8) | 20 (11.3) |  |
Liver metastases | Â | Â | Â | Â | 0.001 |
 No | 308 (79.8) | 85 (73.3) | 88 (67.7) | 152 (85.9) |  |
 Yes | 78 (20.2) | 31 (26.7) | 42 (32.3) | 25 (14.1) |  |
Brain metastases | Â | Â | Â | Â | 0.625 |
 No | 370 (95.9) | 108 (93.1) | 124 (95.4) | 170 (96.0) |  |
 Yes | 16 (4.1) | 8 (6.9) | 6 (4.6) | 7 (4.0) |  |
Bone metastases |  |  |  |  | < 0.001 |
 No | 226 (58.5) | 91 (78.4) | 89 (68.5) | 134 (75.7) |  |
 Yes | 160 (41.5) | 25 (21.6) | 41 (31.5) | 43 (24.3) |  |
Number of metastatic sites | Â | Â | Â | Â | 0.001 |
 1 | 104 (26.9) | 28 (24.1) | 42 (32.3) | 53 (29.9) |  |
 2 | 108 (28.0) | 48 (41.4) | 37 (28.5) | 74 (41.8) |  |
  ≥ 3 | 174 (45.1) | 40 (34.5) | 51 (39.2) | 50 (28.2) |  |
Anti-HER2 therapy during first line | Â | Â | Â | Â | 0.429 |
 Yes | – | 54 (46.6) | 54 (41.5) |  |  |
 No | – | 62 (53.4) | 76 (58.5) |  |  |
DFS |  |  |  |  | < 0.001 |
  ≤ 2 years | 83 (21.5) | 47 (40.5) | 36 (27.7) | 94 (53.1) |  |
  > 2 years | 256 (66.3) | 41 (35.3) | 67 (51.5) | 63 (35.6) |  |
 M1 | 47 (12.2) | 28 (24.2) | 27 (20.8) | 20 (11.3) |  |